Johnson & Johnson: Scleroderma, Systemic trials

The registry lists 10 Scleroderma, Systemic studies with Johnson & Johnson as lead sponsor. 0 are open to participants now and 3 have results posted.

Phase 2 4Phase 3 5Phase 4 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Guselkumab in Participants With Systemic SclerosisCompletedNCT04683029Phase 2Results posted
• Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis PatientsTerminatedNCT01474122Phase 3Results posted
• Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis PatientsCompletedNCT01474109Phase 3Results posted
• Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic SclerosisCompletedNCT02260557Phase 2
• Bosentan in Systemic SclerosisCompletedNCT01395732Phase 4
• Digital UlcerationCompletedNCT01377090
• Early, Simple and Reliable Detection of Pulmonary Arterial Hypertension (PAH) in Systemic Sclerosis (SSc)TerminatedNCT00706082
• Open-label Study With Bosentan in Interstitial Lung DiseaseCompletedNCT00319033Phase 2/3
• Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Patients With SclerodermaCompletedNCT00077584Phase 3
• Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With SclerodermaCompletedNCT00070590Phase 2/3